Dosage ; CHF post myocardial infarction: 25-50mg OD.
Hypertension: 50mg OD to 50mg BD.
Combinations ; - see below
| Brand Name | Manufacturer Name | Distributor | Drug Strength | Packaging | Formulation | Formulation Strength | Price |
|---|---|---|---|---|---|---|---|
| Inspra | Pfizer Global Pharmaceuticals | Surgipharm Ltd | 25mg | 30 | Tablet | per tablet | KES 3,000.00 |
| Inspra | Pfizer Global Pharmaceuticals | Surgipharm Ltd | 50mg | 28 | Tablet | per tablet | KES 2,779.00 |
| Epnone | MSN Laboratories PVT Ltd | Simba Pharmaceutical Ltd. | 25mg | 30 | Tablet | per tablet | KES 2,300.00 |
| Epnone | MSN Laboratories PVT Ltd | Simba Pharmaceutical Ltd. | 50mg | 30 | Tablet | per tablet | KES 2,744.00 |
| Eplerenone More info | |
|---|---|
| Mode Of Action | Aldosterone antagonist |
| Drug Indication | LV systolic dysfunction and CHF after an acute myocardial infarction; hypertension |
| Precautions | Monitor serum potassium levels before and during treatment. |
| Contra-Indications | High serum potassium levels; low creatinine clearance; concomitant use with strong CYP3A4 inhibitors; concomitant use of potassium supplements or potassium-sparing diuretics. |
| Side Effects | Hyperkalemia; increased creatinine; dizziness; diarrhoea; coughing; fatigue; flu-like symptoms. |
| Dosage | CHF post myocardial infarction: 25-50mg OD. Hypertension: 50mg OD to 50mg BD. |
| Drug Category | DRUGS ACTI NG ON THE CARDIO-VASCULAR SYSTEM |
| Drug Sub-Category | Potassium sparing diuretics |